32.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$31.35
Aprire:
$31.41
Volume 24 ore:
356.06K
Relative Volume:
0.61
Capitalizzazione di mercato:
$1.69B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
30.12
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
+4.75%
1M Prestazione:
-2.51%
6M Prestazione:
-5.04%
1 anno Prestazione:
+9.93%
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SUPN
Supernus Pharmaceuticals Inc
|
32.22 | 1.69B | 651.97M | 59.71M | 172.03M | 1.0696 |
![]()
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
2023-01-03 | Ripresa | Jefferies | Buy |
2021-12-01 | Ripresa | Jefferies | Buy |
2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2020-06-15 | Ripresa | Jefferies | Hold |
2019-11-08 | Downgrade | Berenberg | Buy → Hold |
2019-11-07 | Downgrade | Stifel | Buy → Hold |
2019-11-06 | Downgrade | Jefferies | Buy → Hold |
2018-11-12 | Reiterato | B. Riley FBR | Buy |
2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
2017-10-19 | Iniziato | FBR & Co. | Buy |
2017-09-19 | Downgrade | Stifel | Buy → Hold |
2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
2017-07-14 | Iniziato | Janney | Neutral |
2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
2015-11-05 | Reiterato | Northland Capital | Outperform |
2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
LPL Financial LLC Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Bank of Montreal Can Buys 473 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
3 Healthcare Stocks with Mounting Challenges - Yahoo Finance
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 - The Manila Times
Supernus Pharmaceuticals, Inc. to Announce First Quarter 2025 Financial Results on May 6, 2025 - Nasdaq
Supernus Pharmaceuticals to Announce First Quarter 2025 - GlobeNewswire
Supernus Q1 2025 Earnings Preview: CEO Jack Khattar to Detail Financial Performance May 6 - Stock Titan
Federated Hermes Inc. Has $58,000 Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Long Term Investment Analysis - news.stocktradersdaily.com
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Upgraded by StockNews.com - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Holdings Lifted by Franklin Resources Inc. - Defense World
JPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Levi & Korsinsky Reminds Shareholders of an Investigation into Supernus Pharmaceuticals, Inc. (SUPN) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Geode Capital Management LLC - Defense World
Wellington Management Group LLP Sells 2,826 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
SUPN stock soars to 52-week high, hits $39.38 amid growth - MSN
Shareholders that lost money on Supernus Pharmaceuticals, Inc.(SUPN) should contact Levi & Korsinsky about Securities Fraud InvestigationSUPN - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc. (SUPN) - ACCESS Newswire
Norges Bank Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsSUPN - ACCESS Newswire
Arrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - The AM Reporter
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Commonwealth Equity Services LLC - Defense World
ATTENTION Supernus Pharmaceuticals, Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Vanguard Group Inc. Has $222.41 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Several Supernus Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by HighTower Advisors LLC - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by StockNews.com to “Strong-Buy” Rating - Defense World
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses. - ACCESS Newswire
Thrivent Financial for Lutherans Sells 591 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Teacher Retirement System of Texas Has $591,000 Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
ATTENTION SUPN SHAREHOLDERS: Investors who lost money on Supernus Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Swiss National Bank - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Buy” Rating by StockNews.com - Defense World
11,282 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Proficio Capital Partners LLC - Defense World
Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN) - ACCESS Newswire
Raymond James Financial Inc. Takes $6.85 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Taking a Closer Look At Supernus Pharmaceuticals Inc (SUPN) Following Its Recent Trade - knoxdaily.com
(SUPN) Trading Report - news.stocktradersdaily.com
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your Supernus Pharmaceuticals, Inc. Investment - ACCESS Newswire
PNC Financial Services Group Inc. Sells 362 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Atria Investments Inc Invests $288,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Charles Schwab Investment Management Inc. Purchases 40,968 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
DEC TIMOTHY C | Senior Vice-President & CFO |
Mar 10 '25 |
Option Exercise |
0.00 |
3,800 |
0 |
13,636 |
Khattar Jack A. | President, CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
38,640 |
0 |
992,219 |
Mottola Frank | SVP, Quality, GMP, Ops, IT |
Mar 07 '25 |
Option Exercise |
0.00 |
2,625 |
0 |
16,507 |
Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 26 '25 |
Option Exercise |
0.00 |
5,760 |
0 |
17,683 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 21 '25 |
Option Exercise |
0.00 |
1,650 |
0 |
11,799 |
Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
8,780 |
Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Sale |
39.15 |
927 |
36,292 |
7,853 |
Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 21 '25 |
Option Exercise |
0.00 |
1,125 |
0 |
9,576 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Option Exercise |
29.61 |
9,477 |
280,614 |
19,626 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):